ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
March 27, 2017 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr....
ProQR to Present at Two Upcoming Investor Conferences in March
March 01, 2017 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, March 01, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for...
On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
February 27, 2017 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, Feb. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Announces Results for the Third Quarter of 2016
November 14, 2016 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, Nov. 14, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR to Present at Scientific and Investor Conferences in September
September 06, 2016 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for...
ProQR Announces Results for the Second Quarter of 2016
August 17, 2016 07:00 ET
|
ProQR Therapeutics
LEIDEN, the Netherlands, Aug. 17, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation
June 01, 2016 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the company’s investigational drug QR-110 has received orphan drug designation...